sur MedMira, Inc. (CVE:MIR)
MedMira Releases FY2025 Financial Performance
MedMira Inc., based in Halifax, Nova Scotia, has announced its financial results for the year ending July 31, 2025. The year saw the launch of new diagnostic products in Canada, including the Multiplo® Rapid TP/HIV Test and the Reveal® Rapid HIV Test, alongside securing important approvals from Health Canada.
In the U.S., MedMira achieved significant milestones with VA and Federal listings, expanding its distribution network. The firm actively participated in bidding processes, anticipating the FDA CLIA waiver to increase contract opportunities.
Financials showed a decline in revenue to $240,509 from $412,568 in FY2024, with a net loss of $4,524,407, exacerbated by expanded R&D and marketing expenses. Despite the financial setbacks, the company continues to focus on technological advancements, such as the development of its MiROQ technology for improved diagnostics.
Balance sheet adjustments include decreased assets and increased liabilities, predominantly due to strategic financial maneuvers to support operational needs.
R. P.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de MedMira, Inc.